RetinalGenix Technologies Inc. (RTGN)
RetinalGenix Technologies Inc. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Apollo Beach, FL, US. The stock last traded at $4.00, up 0.00% on the session, giving a market capitalisation of $75.4M. On trailing twelve-month figures it carries a trailing P/E of -30.82, a net margin of 0.0%. Its beta of -3.32 implies it has historically moved less than the broad market.
RetinalGenix Technologies Inc. is a company dedicated to research and development within the field of ophthalmology. Its core mission involves devising advanced technologies aimed at detecting, supervising, identifying, and treating a range of visual conditions, including those affecting the eyes and those that could lead to vision loss. Their product lineup features the RetinalGeniX Imaging System, an apparatus for broad-scale retinal imaging and screening that does not require pupil dilation, particularly useful for diabetic patients. Additionally, they offer the RetinalCam, a device designed for real-time retinal monitoring and imaging in a home setting, which includes an alert function for medical practitioners. The company was founded in 2017, with its principal offices located in Petaluma, California. RetinalGenix Technologies Inc. operates as a subsidiary of Sanovas Ophthalmology, LLC.
RetinalGenix Technologies Inc. is most often compared with the following Healthcare names: